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Background: We investigated the influence of baseline and worsening renal function on the efficacy of spironolactone in patients with severe HF.
Methods: We utilized data from the Randomized Aldactone Evaluation Study (RALES) in 1663 pts NYHA class III or IV HF and an ejection fraction 
< 35%. Participants were randomized to spironolactone 25mg or placebo daily. Renal function (eGFR) was estimated by MDRD equation. Worsening 
renal function was defined as rise in creatinine greater than 0.3mg/dl from baseline to 4 weeks post randomization.
Results: Mean eGFR was 64.9±23.0 mL/min/1.73m2 (interquartile range 48.8-77.2 mL/min/1.73m2). Those with eGFR less than 60 mL/
min/1.73m2 (n=866, 52%) were older (70±9 vs 61±12 years, p<0.001) and more likely female (55%, p = 0.001). Treatment with spironolactone 
resulted in 11% absolute mortality reduction in participants with eGFR < 60 versus 6% reduction in the higher eGFR group. Serum creatinine rose by 
> 0.3 mg/dL in 121 (19%) in spironolactone group and 57 (8%) in placebo group (p<0.001). While worsening renal function was associated with 
higher mortality (HR 1.34, 95% CI 1.06-1.7, p=0.017) despite treatment assignment, the relative benefit of spironolactone was preserved.
Conclusions: The absolute benefit of spironolactone was greatest in patients with reduced eGFR. Worsening renal function was associated with a 
negative prognosis, yet the mortality benefit of spironolactone was maintained. 
